Listeria monocytogenes empyema in an HIV infected patient

Anna Marron, Beatriz Rosón, Jordi Mascaró, Jordi Carratalà

Abstract
Listeriosis in HIV infected patients is uncommon and usually presents as meningitis or bacteraemia. Pleural fluid infections caused by this organism are extremely rare. A case is described of empyema caused by Listeria monocytogenes in an HIV infected patient that was successfully treated with medical treatment only.

(Thorax 1997;52:745–746)

Keywords: Listeria monocytogenes, empyema, HIV.

Listeria monocytogenes is a Gram positive motile bacillus that mainly affects subjects with defects in cell mediated immunity, pregnant women, or neonates. Listeriosis usually presents as meningitis or bacteraemia, although other manifestations such as septic arthritis, brain abscess, infective endocarditis, endophthalmitis, and hepatitis have been described. Pleural fluid infections caused by L monocytogenes are extremely rare. We report a case of L monocytogenes empyema in an HIV infected patient.

Case report
A 33 year old woman, a former intravenous drug abuser who was HIV infected and a heavy drinker, presented to our hospital with a 48 hour history of fever, non-productive cough, pleuritic left pain, and shortness of breath. Two years before admission biopsy proven liver cirrhosis was documented. She had had several previous admissions for ascites, spontaneous bacterial peritonitis, or spontaneous bacteremia. No HIV related pathology was known. She was receiving zidovudine 500 mg daily and prophylaxis with aerosolised pentamidine instead of trimethoprim-sulphamethoxazole. One year later the patient remains alive and no other listerial infections have been documented.

Listeriosis in HIV infected patients is uncommon and usually presents as meningitis or bacteraemia. Pleural fluid infections caused by this organism are extremely rare. A case is described of empyema caused by Listeria monocytogenes in an HIV infected patient. The initial treatment with intravenous ceftixime was then discontinued and intravenous ampicillin 2 g every four hours plus gentamicin 200 mg daily were administered for 14 days. After four days of antibiotic therapy both blood and pleural fluid cultures were negative and the patient was discharged on oral trimethoprim-sulphamethoxazole. One year later the patient remains alive and no other listerial infections have been documented.

Discussion
A population based study has shown that patients with AIDS have an increased risk of developing invasive listeriosis of up to 145 times that of the general population. However, listeriosis has rarely been described in HIV infected patients, and most of the reported cases presented as meningitis and bacteraemia. To our knowledge only one case of pleural fluid infection with L monocytogenes in an HIV infected patient has been previously reported. It should be noted that, as in our case, that patient also had chronic liver disease, a condition that could have been an additional predisposing factor for invasive listeriosis. In addition, our patient was receiving inhaled pentamidine instead of trimethoprim-sulphamethoxazole which may also have contributed to development of infection. Haematogenous spread and secondary seeding of the pleura seems to be the route of infection in most cases of pleural fluid infection caused by L monocytogenes, as we think occurred in our patient. Conversely, the HIV infected patient previously described had pneumonia and developed an effusion probably as a parapneumonic process since blood cultures yielded no bacteria. Neither ascites nor abdominal pain was present, although the association of listerial empyema with spontaneous bacterial peritonitis has also been recognised. High doses of ampicillin or penicillin, together with an aminoglycoside, is the treatment of choice for listeriosis, principally when poor prognostic indicators are present. Trimethoprim-sulphamethoxazole, commonly given to AIDS patients for prophylaxis of Pneumocystis carinii infection, is also an effective therapy for listeria...
OCCUPATIONAL ASTHMA IN AN ISOThIAZOLINONE MANUFACTURING PLANT

S J Bourke, R P Convery, S C Stenton, R M Malcolm,* D J Hendrick

Department of Respiratory Medicine and Regional Unit for Occupational Lung Disease, Newcastle General Hospital, University of Newcastle upon Tyne, UK
S J Bourke R P Convery S C Stenton R M Malcolm D J Hendrick

*Present appointment: Chief Medical Officer, Tayside Police.

Correspondence to: Dr S J Bourke, Department of Respiratory Medicine, Royal Victoria Infirmary NHS Trust, Newcastle General Hospital, Newcastle upon Tyne NE4 6BE, UK.

Revised version received 22 August 1996
Accepted for publication 26 September 1996

Occupational asthma in an isothiazolinone manufacturing plant

S J Bourke, R P Convery, S C Stenton, R M Malcolm,* D J Hendrick

Abstract
A chemical plant operator developed asthma five months after starting work in an isothiazolinone manufacturing plant. He described symptoms of late asthmatic reactions after work with isothiazolinone.

Airway responsiveness to methacholine improved tenfold when he was removed from the plant for 18 days. A workplace challenge study then resulted in a deterioration in airway responsiveness to its earlier level and in progressive falls in forced expiratory volume in one second (FEV1) over three days at work compared with control days, indicating statistically significant late asthmatic reactions of increasing severity.

(Thorax 1997;52:746–748)

Keywords: occupational asthma, biocides, isothiazolinone.

Isothiazolinones are being used increasingly as broad spectrum biocides in various water systems and in products such as paper, paints, and cosmetics.1 2 In some circumstances they have been used as substitutes for formaldehyde and glutaraldehyde which are known to cause asthma.3 There have been many reports of isothiazolinones causing occupational dermatitis but evidence of asthma due to isothiazolinones is lacking.4 5 We describe the occurrence of asthma in an isothiazolinone manufacturing plant, and a workplace challenge study which suggested it was occupational in origin. We think it likely that this was the result of sensitisation to isothiazolinone.

Case report
A 53 year old chemical plant operator developed asthma five months after starting work in an isothiazolinone manufacturing plant. He had no previous history of asthma or atopic disease and he was an ex-smoker. His job involved the filling of containers with various formulations of isothiazolinones in aqueous solution, including a combination of 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one. This was performed in an enclosed booth fitted with an extractor, but as he frequently opened the door of the booth to replace containers there was potential exposure to low concentrations of airborne isothiazolinone, which is weakly volatile. He described symptoms of cough and wheeze, which occurred towards the end of his working shifts, persisted into the evenings after work, and often disturbed his sleep at night. He was diagnosed as having asthma by his general practitioner and was prescribed salbutamol and beclomethasone inhalers. He noticed that his symptoms were related to his work and he had tried to reduce his exposure, but he remained at the same job over the next five years until he was referred for assessment. His forced expiratory volume in one second (FEV1) was 3.91 litres (109% predicted) and his forced vital capacity (FVC) was 5.69 litres (127% predicted) while taking salbutamol and beclomethasone, and he had moderate airway responsiveness to methacholine with a provoking dose responsible for a 20% fall in FEV1 (PD20) of 230 μg. Skin tests for atopy gave negative results. His history was suggestive of occupationally provoked late asthmatic reactions and a workplace challenge study was undertaken.

Workplace challenge study
His asthma treatment was stopped, he was withdrawn from the workplace for 18 days, and then re-exposed to his normal work environment. Spirometric tests were performed hourly from 07.00 hours to 17.00 hours on three control days away from work, and hourly from 07.00 hours to 23.00 hours on a fourth control day. He then returned to his normal job, working a 07.00 hours to 15.00 hours shift,
Figure 1 Serial measurements of FEV₁ during workplace challenge study.

and spirometric testing was performed hourly from 07.00 hours to 23.00 hours on three consecutive work days. He spent each shift as usual filling containers with isothiazolinone formulations containing a mixture of 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one. This was performed as an enclosed process within the booth but he opened the door of the booth frequently throughout the shift, as usual, putting containers in place and screwing on their lids.

On each of the three study days at work he developed nasal irritation, cough, wheeze and chest tightness starting 4–6 hours into the shift and persisting into the evening with sleep disturbance at night. Figure 1 shows the mean FEV₁ values for the control days 1–3 (07.00–17.00 hours), a “lower boundary” equivalent to a 95% confidence limit, and evening values (18.00–23.00 hours) for control day 4. Superimposed are the plots for the three days at work. Each crosses the “lower boundary” at a progressively earlier time and with progressively greater strength, indicating statistically significant late asthmatic reactions of increasing severity.⁶ Airway responsiveness to methacholine was measured on four occasions. On his last day at work before the study the PD₂₀ was 115 μg; on days 10 and 18 away from work it improved sequentially to 267 μg and 1107 μg, but three days after his return to work it had deteriorated to 110 μg.

Air monitoring in the manufacturing plant had shown low but measurable levels of isothiazolinone of 0.01–0.3 mg/m³. These were well within the control limits set internally by the manufacturer in order to avoid possible irritant effects. Out of a total of 20 workers in the plant two others developed symptoms of asthma after beginning employment. Both then changed the nature of their work so that the possibility of ongoing exposure to isothiazolinone was much reduced. One recovered fully and the other, a maintenance technician, improved. However, the maintenance technician was subsequently involved in an accident which resulted in facial and eye contact with dissolved isothiazolinone. This caused a brief period of conjunctival inflammation but not worsening asthma.

Discussion

The clinical history of the chemical plant operator was strongly suggestive of occupational asthma in that he had developed asthma de novo after a short latent interval of employment, with a close relationship between symptoms and periods at work. The workplace challenge study provided objective evidence of statistically significant late asthmatic reactions occurring at progressively earlier times and with progressively greater magnitude on each of the three successive days during which he worked with isothiazolinone.⁷ This suggests increasing levels of airway responsiveness during the study period.

Changes in airway responsiveness associated with emergent or resolving occupational asthma (or with inhalation provocation tests) may be rapid and dramatic, though such changes in asthmatic activity are rarely seen in other circumstances.⁷ The significance of changes of PD₂₀ can be assessed when population samples undergo two methacholine tests and the coefficient of repeatability (CR) is calculated. Estimates for CR using our dosimeter method for methacholine tests have given values in the range of 2–3, indicating that an increase in PD₂₀ to threefold or a decrease to one third identifies a statistically significant change.⁸ During the period of investigation in this case the PD₂₀ values increased approximately tenfold over the 18 day period away from work and then fell to almost exactly the initial value on re-exposure to the work environment for three days. The importance of being able to identify significant changes in airway responsiveness in association with inhalation provocation tests is that the test agent or environment can be shown to be a potential inducer of asthma, not merely a provoker of asthmatic attacks.

The workplace challenge study in this case consequently provided strong evidence for a diagnosis of occupational asthma, and the suspicion that two of 20 fellow workers had similarly developed asthma provides additional support. The nature of the operator’s work, the known sensitising properties of isothiazolinone in the skin, and the confirmed presence of respirable isothiazolinone (albeit in low concentrations) in the work environment suggest that isothiazolinone was the cause. We think this is likely, and we assume that isothiazolinone, like many reactive chemicals of low molecular weight, acts as a hapten through immunological mechanisms. This is thought to explain its effect in causing dermatitis.⁹ Our investigations do not prove a causal relationship, however, and there is a need for specific inhalation provocation tests to provide definitive conclusions.

Sodium metabisulphite is used in the plant to inactivate isothiazolinone following accidental spillages, and this substance has been reported to cause immediate asthmatic reactions fol-
Regression of polyvinylchloride polymer pneumoconiosis

Neil W White, Rodney I Ehrlich

Abstract
A 35 year old man heavily exposed to polyvinylchloride (PVC) polymer dust developed dyspnoea and a mild restrictive lung disorder consistent with PVC pneumoconiosis. Clinical and radiological abnormalities cleared on removal from exposure, suggesting that in its early stages PVC pneumoconiosis is reversible.

(Keywords: polyvinylchloride, pneumoconiosis, lung disease)

Case report
In November 1991 a 35 year old plastics factory employee presented with sore throat, blocked nose, chest tightness, and pleuritic chest pains. Physical examination and chest radiography were normal. Pulmonary function test values were at the lower limit of normal (table 1).

In July 1993 he returned with persistent sore throat, nasal and eye irritation, occasional dyspnoea, and a non-productive cough which had been present for several months. His effort tolerance had declined and he was no longer able to play soccer. A detailed occupational history established that he had worked since 1985 primarily with a fine polyvinylchloride (PVC) powder, manually loading hoppers under very dusty conditions using only a simple mask as respiratory protection. A visit to the factory confirmed his description; there was no local exhaust ventilation and general ventilation was inadequate. Various pigments and other chemicals were added to the PVC, but he was not involved in this later part of the process.

He had never smoked, had no domestic bird exposure, no tuberculosis contact, nor any history suggestive of allergy or atopy. Examination showed sparse fine crackles over the left lower zone. Full blood count, differential count, international normalised ratio, and serum levels of angiotensin converting enzyme (ACE) were normal.

Pulmonary function testing showed a reduction of more than 600 ml in volumes and abnormalities cleared on removal from exposure, suggesting that in its early stages PVC pneumoconiosis is reversible.

identified in the macrophages by scanning electron microscopy.

In November 1993, three months after removal from exposure to PVC powder, improvement in the pulmonary function tests was noted (table 1). By June 1994 he was asymptomatic, with lung function values close to those at his first visit in 1991. On repeat HRCT scanning the nodularity present a year before was much less evident.

**Discussion**

Pulmonary reaction to polyvinylchloride polymer dust has been documented in epidemiological and histological studies. Clinically, PVC pneumoconiosis is a diagnosis of exclusion in the context of appropriate exposure. Sarcoïdosis was the main alternative diagnosis here, but the absence of extra-pulmonary clinical features, normal serum levels of ACE, the absence of non-caseating granulomas on transbronchial biopsy specimens, and no characteristic features on the HRCT scan effectively excluded this possibility. Furthermore, the natural history of his complaint and the absence of corresponding positive features were thought to exclude tuberculosis and connective tissue disorders. No risk factors for an extrinsic alveolitis were identified. The only environmental modification that occurred prior to his improvement was his removal from exposure to PVC dust.

Histological examination showed focal areas of fibrosis and conspicuous fibrin in the interstitium, but not some of the features documented in heavily dusted experimental animals and in case reports of workers with respiratory disease following heavy exposure to PVC who died or from whom lung biopsy samples were taken. Intracellular foreign particles have been seen in macrophages by scanning electron microscopy of specimens from heavily dusted animals. The other case report in English which described a lung biopsy specimen found that the nodules represented a histiocytic infiltrate in a collagen matrix. These histiocytes/macrophages have clear vacuoles with a few multinuclear giant cells also present.

The non-specific abnormalities in the airways and parenchyma seen in our case could reflect limited biopsy tissue. Alternatively, we may have documented an earlier stage or milder form of PVC pneumoconiosis, where macrophage mediated fibrosis is limited and largely reversible.

Our patient developed mild ventilatory restriction and slightly reduced gas transfer. Respiratory symptoms, pulmonary function changes, and abnormalities on the chest radiograph have been documented in cross sectional studies of workers employed in PVC production and fabrication. In two studies exposure to PVC dust was associated with mild functional restriction and small rounded or irregular opacities of low profusion radio-complaint and the absence of corresponding description suggesting that PVC pneumoconiosis might regress. This case suggests that in its early stages or after a relatively short exposure, PVC pneumoconiosis is largely reversible. Further longitudinal studies are needed before we fully understand the natural history of PVC pneumoconiosis.

---

**Table 1 Serial changes in pulmonary function**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV₁ (ml)</td>
<td>2440</td>
<td>1800</td>
<td>2120</td>
<td>2360</td>
<td>2400</td>
<td>3270 (840)</td>
</tr>
<tr>
<td>FVC (ml)</td>
<td>3050</td>
<td>2570</td>
<td>2750</td>
<td>2990</td>
<td>3170</td>
<td>3850 (1000)</td>
</tr>
<tr>
<td>FEV₁/FVC (%)</td>
<td>80</td>
<td>76</td>
<td>77</td>
<td>79</td>
<td>76</td>
<td>85</td>
</tr>
<tr>
<td>TLCO (mmol CO/kPa/min)</td>
<td>78.6</td>
<td>68.7</td>
<td>77</td>
<td>79</td>
<td>84.3</td>
<td>80.4 (82.8)</td>
</tr>
<tr>
<td>Kco (mmol CO/kPa/min/l)</td>
<td>20.7</td>
<td>19.8</td>
<td>21.3</td>
<td>21.3</td>
<td>18.3</td>
<td>18.3 (3.5)</td>
</tr>
</tbody>
</table>

FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity; TLCO = single breath carbon monoxide diffusing capacity; Kco = TLCO/alveolar volume.

---

Listeria monocytogenes empyema in an HIV infected patient.

A Marron, B Rosón, J Mascaró and J Carratalà

Thorax 1997 52: 745-746
doi: 10.1136/thx.52.8.745